The Latest On Premier Science In Medical Oncology At The 33rd ESMO Congress, Stockholm, Sweden, Sept. 12-16, 2008

Main Category: Cancer / Oncology
Also Included In: Conferences;  Radiology / Nuclear Medicine;  Medical Devices / Diagnostics
Article Date: 01 Aug 2008 - 0:00 PST

email to a friend   printer friendly   view / write opinions   rate article

Congress Highlights

Some of the highlights that will be presented during the educational and scientific program at Europe's premier medical oncology meeting include:

• Molecular analysis for target discovery: Identification of 'Achilles' heel'
  MicroRNa, SiRNA libraries
  Protein array
  
  
• Innovation in breast cancer
  Modulation of resistance to anti-Her2 therapies
  Evaluation of predictive markers on circulating tumor cells
  New targets for triple negative tumors
  Stem cell as a potential target
  Tools in daily clinical practice to improve treatment
  
  
• Tailoring therapy in lung cancer
  Medical implications of resistance to EGFR
  Personalized cancer therapies for non-EGFR receptor-dependent tumors
  
  
• New pathways in targeted therapy
  IGF-1, PI 3, PARP, Met
  
  
• Optimal integration of newer agents in the treatment of advanced CRC
  Genomic and pharmacogenetic markers for treatment decision
  Upfront sequential vs. combination chemotherapy
  
  
• Renal cell cancer
  VEGF biology and resistance
  mTOR
  Tackling future issues
  
  
• Hitting the cell in ovarian and endometrial cancers
  PARP, mTOR, etc
  
  
• Head and neck cancer
  Viruses: Prevention and therapy
  Innovations in radiation oncology (IMRT and image guided radiotherapy)
  How to integrate EGFR inhibitors and beyond
  
  
• Hematological malignancies
  The role of high-dose therapy and allografting stemcell transplantation in the era of '-nibs' and '-mabs'
  
  
• Communication skills in advanced cancer care o The use of communication skills: Lessons derived from microanalytical studies
  
  
• Advances in soft tissue sarcoma, GIST and beyond
  GIST - the role of adjuvant therapy and mutational analysis in treatment decision-making
  Molecular biology and targeted therapy of sarcomas
  Hyperthermia improves local control of STS - where next?
  
  
• Emerging therapies for rare tumors
  Neuroendocrine tumors, HCC, thyroid cancer, papillary RCC
  
  
• Assessing, reporting and managing the safety of cancer drugs
  Detecting safety signals
  The role of pharmacogenetics in predicting and managing toxicity
  Handling side effects of targeted therapies
  
  
• Integration of targeted therapies with radiation
  Where we are with radiation modifiers?
  
  
• Unplanned analysis of molecular studies
  Harmful or safe?
  
  
• Cancer patients
  o Should all receive prophylactically antithrombotic therapy?
  o Dealing with difficult cases in daily clinical practice
  
  
  
• New developments in myeloma
  Prognostic factors and the role of novel drugs
  The status of transplantation
  
  
• Glioma
  From imaging to management
  
  
• Recent progress in immunotherapy
  Anti cancer vaccines
  Combining immunotherapy with classical anti-cancer therapy
  
  
• Advanced prostate cancer
  The changing face of hormonal therapy
  Diabetes and cardiovascular disease in prostate cancer survivors
  
  
• Latest on oncology in developing countries
  Cancer burden and the role of prevention
  Balancing costs and benefits in cancer therapy and prevention
  
  
• Drug development
  How to recognize a promising drug: The role of clinical and biological endpoints
  The role of regulatory bodies in the drug approval process

The Highlights of the day session: summary sessions of topics from the preceding day aiming to give an overview of the most interesting and important points to emerge from previous sessions.

Late-breaking abstracts: oral sessions to present latest research studies with new research findings

Controversy sessions will create lively discussions on hot topics.

The 7th ESMO Patient Seminar where patients will have the chance to meet oncologists and hear about the conditions of cancer treatment in Europe, comparing conditions in Eastern and Western countries; discuss and confront doctors about the consequences of cancer therapy, learn the approaches to long-term survivorship and the future perspective of cancer treatments

Numerous Educational Sessions to present state-of-the-art oncology.

The fifth batch of ESMO Designated Centers of Integrated Oncology and Palliative Care will be announced as centers of excellence for patient care in Europe.

A session on ESMO Clinical Recommendations will update current ESMO Guidelines on clinical practice for various tumor types.

Oncology Highlights of the most important advances in cancer treatment in 2008.

And… Her Majesty Queen Silvia of Sweden accepted to be the Patron of the 33rd ESMO Congress and will give the welcome address during the Opening Ceremony

Meeting venue

The 33rd ESMO Congress will take place at the Stockholm International Fairs in Älvsjö, (Mässvägen 1, SE-12580 Stockholm-Älvsjö), located a short train journey from Stockholm Central Station.

The conference full program is available at http://www.esmo.org/activities/esmocongress/stockholm08/program_cng/

Accomodation

Congrex Sweden AB has been appointed by ESMO to manage hotel accommodation in relation to the 33rd ESMO Congress For hotel reservation, please visit: http://www.esmo.org/activities/esmocongress/stockholm08/accommodation_cng/

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

About the European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading European non-profit, professional organization for medical oncology promoting multidisciplinary cancer treatment around the world.

ESMO unites medical oncologists and other oncology specialists, healthcare professionals, caregivers, patients, policy-makers and all the key stakeholders in a global alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Through state-of-the-art education and training programs, ESMO plays an instrumental role in providing the oncology community with the most up-to-date scientific research and information available. ESMO is dedicated to educating and supporting oncologists, optimizing patient care, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative voice in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment. Through its flagship journal, Annals of Oncology, ESMO publishes articles on all aspects of clinical oncology.

To find out more about ESMO please visit http://www.esmo.org/

Source: Vanessa Pavinato
European Society for Medical Oncology